FDA approves Fonar open scanner

Article

Fonar introduced its “Open Sky” scanner room two years ago at the Radiological Society of North America meeting, and this month the Melville, NY-based company moved one step closer to putting the system on the market.The Food and Drug

Fonar introduced its “Open Sky” scanner room two years ago at the Radiological Society of North America meeting, and this month the Melville, NY-based company moved one step closer to putting the system on the market.

The Food and Drug Administration has given Fonar premarket approval for the Fonar 360, which is the platform scanner for the Open Sky. The Fonar 360 will have a 0.6-tesla field strength.

Fonar says the company has ushered in a new era of patient friendliness in MR with its work-in-progress Open Sky room. Patients will walk into the scanner room in which two circular structures projecting from the ceiling and floor are the only objects. There’s nothing else—no posts, no tube they must climb into—between the patient and the scanner room walls.

The walls are decorated with a landscape scene, and the room is quiet thanks to Fonar’s patented sound-dampening system. Patients will also be able to choose which landscape setting they would like. The large circular structures that the patient sees as part of the landscape are the poles of the scanner’s magnet.

Last year, healthcare services contributed more to Fonar’s revenue than scanner sales.

During its 1999 fiscal year (end-June), Fonar posted revenue of $36.9 million, a 34% increase over 1998’s $27.6 million, but also sustained a net loss of $14.2 million. Fonar attributed the loss to low scanner sales and expenses related to the R&D of four new MRI products (SCAN 11/10/99). Fonar believes that its new scanners, including the Open Sky, will lead to sales growth (SCAN 3/3/99).

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.